Arvinas

Arvinas is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in the United States. The company is committed to developing targeted protein degradation therapeutics with the aim of improving the lives of patients suffering from debilitating and life-threatening diseases. Their proprietary PROTAC® Discovery Engine platform enables the engineering of PROTAC® targeted protein degraders, which leverage the body’s natural protein disposal system to selectively degrade and remove disease-causing proteins. Arvinas boasts a robust preclinical pipeline of PROTAC® protein degraders targeting validated and “undruggable” proteins and has two clinical-stage programs: ARV-110 for metastatic castrate-resistant prostate cancer and ARV-471 for locally advanced or metastatic ER+\/HER2- breast cancer. One of the notable achievements of Arvinas is the $350.00M Post-IPO Equity investment received on 27 November 2023. The investment was made by prominent firms such as RA Capital Management, Boxer Capital, ArrowMark Partners, BB Biotech Ventures, EcoR1 Capital, RTW Investments, Great Point Partners, Citadel Global Equities, Surveyor Capital, and Avidity Partners. In summary, Arvinas stands at the forefront of biotechnology and pharmaceutical industries, offering innovative therapies and attracting substantial investments to support its groundbreaking research and development efforts. For more information, visit www.arvinas.com.